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Liver transplantationApproximately 20% of patients receiving liver transplants for end-stage hepatitis C rapidly develop severe
allograph ﬁbrosis within the ﬁrst 24 months after transplant. Hepatitis C virus (HCV) variants were studied
in 56 genotype-1-infected subjects with end-stage hepatitis C disease at the time before and 12 months after
liver transplant, and post-transplant outcome was followed with serial liver biopsies. In 15 cases, pre-
transplant HCV genetic diversity was studied in detail in liver (n=15), serum (n=15), peripheral blood
mononuclear cells (n=13), and perihepatic lymph nodes (n=10). Our results revealed that pre-transplant
HCV genetic diversity predicted the histological outcome of recurrent hepatitis C disease after transplant.
Mild disease recurrence after transplant was signiﬁcantly associated with higher genetic diversity and
greater diversity changes between the pre- and post-transplant time points (p=0.004). Meanwhile, pre-
transplant genetic differences between serum and liver were related to a higher likelihood of development of
mild recurrent disease after transplant (p=0.039).743, Seattle, WA 98104, USA.
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Hepatitis C virus (HCV) is an enveloped, positive-strand RNA virus
that circulates in vivo as a population of rapidly mutating yet closely
related variants known as viral quasispecies. In nature, HCV infects
only human, and disease manifestations are highly variable, ranging
from self-limiting acute infections (∼20%) to progressive chronic
hepatitis C (∼80%). Despite high levels of persistent viremia during
the majority of chronic infections, only 20–30% of such cases progress
to cirrhosis, and progression typically occurs over several decades. The
long disease incubation period and highly variable natural history are
intriguing and also major impediments to hepatitis C pathogenesis
studies.
Liver transplantation, a life-saving intervention for many patients
with end-stage hepatitis C disease, provides an extremely valuable
model for studying HCV biology and disease progression over
relatively short time intervals (Gretch et al., 1995, 1996). In this
model, de novo infection of liver allografts by HCV is virtually
universal, and most patients have high titers of HCV viremia by the
second post-transplant week. Severe hepatitis C disease rapidly recurs
in about 20% of cases, leading to accelerated cirrhosis in liver allograftswithin 5 years (Berenguer et al., 2000; Terrault, 2005). In contrast,
approximately 50% of HCV genotype-matched cases have completely
asymptomatic post-transplant infections despite persistence of high
titers of HCV viremia and potent anti-rejection immunosuppressive
therapy. Although evidence suggests that pre-transplant HCV viral
load (Berenguer et al., 2000; Charlton et al., 1998), HCV genotype
(Charlton et al., 1998; Feray et al., 1995; Gane et al., 1996; Sugo et al.,
2003), number of rejection episodes (Sheiner et al., 1995; Sugo et al.,
2003), and type and degree of immunosuppression (Berenguer et al.,
1998) are all associated with severity of HCV recurrence, solid
conclusions about the determinants of recurrence outcome have not
been available. HCV genetic heterogeneity in pre-transplant serum
has also been proposed as a possible predictor of the outcome of
recurrent disease (Gretch et al., 1996; Hassoba et al., 1999; Sullivan
et al., 1998).
Although chronic hepatitis C is associated with a myriad of
extrahepatic disease syndromes (Galossi et al., 2007), HCV replication
in extrahepatic tissues remains poorly understood. Viral RNA has been
detected in peripheral blood mononuclear cells (PBMCs), perihepatic
lymph nodes, or central nervous system with diversiﬁed variants
distribution from serum (Laskus et al., 1998; Navas et al., 1998; Pal
et al., 2006; Radkowski et al., 2002; Roque Afonso et al., 1999; Roque-
Afonso et al., 2005; Vargas et al., 2002). Also, HCV variants within the
liver have been observed to differ from the variants in the circulation,
suggesting the existence of independent viral compartments (De
Table 1
Clinical characteristics of the study groups of subjects that underwent liver
transplantation and developed mild or severe post-transplant disease.
Characteristic Mild Severe
(n=48) (n=8)
Liver allograft donor
Median age (range) 26 (10–62) 31.5 (9–56)
Gender
Male 37 7
Female 11 1
Race
Caucasian 41 7
African 3 0
Hispanic 0 0
Others a 4 1
Liver transplant recipient
Median age (range) 45 (35–69) 47.5 (38–67)
Gender
Male 40 5
Female 8 3
Race
Caucasian 42 7
African 3 0
Hispanic 3 1
Others a 0 0
HCV genotype
1a 32 5
1b 16 3
Histologic biopsy follow-up
Median number (range) 6 (2–15) 6 (4–10)
Median length in months (range) b 36 (12–163) 21 (7–102)
Note. The groups with mild and severe recurrent disease were compared using the
Pearson Chi-square test for the gender, race, and genotype or theMann–Whitney U-test
for the other characteristics. The difference between the groups was not signiﬁcant
unless speciﬁcally indicated.
a Others include Native Americans, Paciﬁc Islanders, and races unknown.
b Mild vs. severe, p=0.031.
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the above evidence, extrahepatic tissues have been suggested to
function as important HCV reservoirs and explain for the high rate of
HCV therapeutic resistance. In post-transplant setting, the primary
source of allograft reinfection is likely to come from the variants in
circulation of the transplant recipient, while the variants derived from
extrahepatic reservoirs, especially PBMCs, may also contribute to the
circulating variants and serve as the origin of reinfection (Dahari et al.,
2005; Laskus et al., 2002).
In the present study, genetic heterogeneity of pre-transplant HCV
variants was analyzed in detail and related to severity of post-
transplant disease recurrence. Genetic tools were used to explore and
compare HCV variants in the serum, liver, and extrahepatic tissues of
human subjects with end-stage hepatitis C disease. We tested the
hypothesis that HCV genetics at the time of liver transplantation is
predictive of the early post-transplant disease course, based on
extremely heavy sampling of infected allografts for disease activity.
Results
Characteristics of the study population
All the 56 patients were infected with HCV genotype 1 before
transplant, with mixed or multiple genotype HCV infections ruled out
using a highly sensitive Core/E1-based probe hybridization assay as
recently described (Li et al., 2008b). A median of 6 follow-up liver
biopsies was carried out per patient to evaluate the histological
recurrence of hepatitis C disease after transplant, and the follow-up
period ranged from a median of 36 months in the patients with mild
recurrent disease to a median of 21 months in the patients with
severe recurrent disease. Forty-eight patients were classiﬁed in the
mild recurrent disease group based on the ﬁbrosis stage during the
initial 12 months after transplant (ﬁbrosis stage 0 or 1), while eight
patients were classiﬁed into the severe recurrent disease group with
either bridging ﬁbrosis or cirrhosis during the initial 12 months after
transplant (ﬁbrosis stage 3 or 4), or ﬁbrosis stage 2 combined with
severe, evolving inﬂammation deﬁned histologically as bridging
necrosis. The clinical characteristics of the two groups with mild
versus severe disease recurrence were shown in Table 1. No
signiﬁcant differences existed between the two groups with respect
to donor or recipient age, gender, race, immunosuppressive use, or
allograft rejection episodes.
Heteroduplex mobility analysis of pre- and post-transplant serum variants
HCV variants in pre-transplant and 12-month post-transplant
serum samples were evaluated with heteroduplex mobility analysis
(HMA) targeting the hypervariable region 1 (HVR1) of the envelope
E2 gene (Gretch et al., 1996). As demonstrated in previous studies, the
shift distance of heteroduplex and homoduplex bands from the top of
the gel gave a precise indication of nucleotide sequence similarities
between the probe and target fragments (Polyak et al., 1997; Wilson
et al., 1995). Analysis of heteroduplex mobility ratio (HMR)
demonstrated greater viral diversity at both pre-transplant and
post-transplant time points in patients with mild recurrent disease
compared to those with rapid severe recurrent disease (Fig. 1A). The
median HMR at the time of pre-transplant was 0.992 and 0.995 for the
groups with mild and severe recurrent diseases, respectively. The
HMR of the mild group showed great diversiﬁcation 12 months after
transplant (median 0.937), while the HMR of the severe group
remained relatively stable (median 0.995). The difference of post-
transplant HMR was statistically signiﬁcant between the two groups
(p=0.008). Fig. 1B further shows that the rate of change in viral
diversity over time (delta HMR) between the pre- and post-transplant
samples differed signiﬁcantly between the two groups, with greaterchanges in those with mild disease recurrence (median 4.6% and 0%
for the mild and severe groups, respectively, p=0.004).
Pre-transplant HCV genetic diversity correlated with recurrent disease
Specimens from tissue reservoirs, including liver, perihepatic
lymph node, and peripheral blood mononuclear cells (PBMCs), were
available from a subset of 15 patients (10 mild and 5 severe cases) at
the pre-transplant time point. HCV variants were detected in all 15
liver specimens, 10 of the lymph nodes, and 13 of the PBMCs (5 of the
lymph node samples and 2 of the PBMC samples were HCV RNA
negative). Using the clonal frequency analysis previously described
(Wilson et al., 1995), a total of 1035 variants (18 to 23 variants per
sample) were characterized by gel electrophoresis, and a total of 282
variantswere identiﬁed as unique variants and subjected to nucleotide
sequencing (GenBank Accession No. GU169906–GU169994,
GU170008–GU170200). Fig. 2 shows the phylogenetic tree of the
unique sequences of serum specimens from each of the patient, along
with the reference genotype 1a and 1b sequences and a genotype 2a
sequence as an outgroup. As shown in the ﬁgure, the variants formed
two major clades on the phylogenetic tree based on the HCV
subgenotypes (1a and 1b). The variants segregated only with others
from the same individual host, and intermingling of variants from
subjects with various disease outcomes was observed for each clade.
When comparing HVR genetic diversity across the tissue samples,
serum variants had the highest genetic heterogeneity, while lower
heterogeneity was found in liver, lymph node, and PBMC compart-
ments. Compared to the subjects in the mild post-transplant disease
category, the group with severe recurrent disease showed signiﬁcant
lower mean values of synonymous and non-synonymous substitutions
of the serum-derived variants (p=0.019 for dS and p=0.028 for dN,
Fig. 1. Evaluation of HVR1 genetic heterogeneity with heteroduplex mobility analysis.
(A) Heteroduplex mobility ratios in subjects with mild and severe recurrent disease at
pre- and post-transplant time points; (B) the percentage of change in heteroduplex
mobility ratios in subjects with mild and severe recurrent disease between the pre- and
post-transplant time points.
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observedwithin the viral variants isolated from the pre-transplant liver,
lymph node, and PBMC specimens of subjects with severe hepatitis C
recurrence. In all four compartments, themean intra-population dN/dS
ratio also tended to be lower in the patients with severe recurrent
disease, although signiﬁcant difference was only found in the liver
compartment (p=0.049, Fig. 3C). HVR1 genetic distances, evaluated at
the nucleotide and amino acid levels, are summarized in Fig. 3D and E.
Higher genetic distances were associated with mild recurrent disease,
and statistical signiﬁcance was found with respect to the nucleotide
distances of serum, liver, and PBMC variants, and the amino acid
distances of the variants from all the four compartments. When
comparing across the compartments, the serum-derived variants had
a mean nucleotide distance of 0.052 and a mean amino acid distance
of 0.100, representing the highest genetic diversity of the four
compartments.Pre-transplant HCV genetic differences in multiple compartments
correlate with recurrent disease
The heteroduplex mobility analysis, while applied to the speci-
mens from multiple compartments of the same individual, provided
direct evidence of genetic diversity of the HCV variants. Fig. 4 showsFig. 2. A phylogenetic tree of the unique serum-derived variants from the 15 patients with
method based on the nucleotide sequences using the PAUP software. Five known sequence
were included as genotype references along with a genotype 2a sequence (2a.JP.JFH-1) as an
with M and S indicating the mild or severe post-transplant outcomes, respectively. The sca
nucleotide sites.the HMA gel shifts of the variants derived from serum, liver, lymph
node, and PBMCs from two representative subjects (panel A, M5 with
mild recurrent hepatitis, and panel B, S5 with severe recurrent
disease) along with the bar ﬁgure of major variant composition and
the alignment of variant nucleotide sequences. As shown in panel A,
each of the compartments displayed multiple bands of heterodu-
plexes that migrated at a retarded distance compared to the
homoduplex band representing the shifting distance of the major
variant in serum. Nucleotide sequencing further conﬁrmed that the
compartments harbored unique variants other than the major variant
in serum. For the subject S5 that developed severe recurrent disease
(panel B), the migration distances of the hereroduplex bands
appeared to be highly similar to the homoduplex control on the
HMA gel shift. Only minor difference was found among the
compartments of serum, liver, lymph node, and PBMCs, and the
difference was associated with only one or two nucleotide inconsis-
tence (see the alignment of nucleotide sequences). Overall, the HMA
gel shifts were performed in 13 out of the 15 subjects and revealed
differences of heteroduplex migration patterns among the compart-
ments in 7 out of 8 subjects with mild recurrent disease (M2, M3, M5,
M6, M7, M10, M11) and 3 out of 5 subjects with severe recurrent
disease (S2, S4, S5). Interestingly, minor differences of heteroduplex
migration patterns were found in all the three cases with severe
disease outcomes.
With sequences available, the genetic differences of HVR1 variants
were quantitatively evaluated using the phylogenetic analysis and the
Mantel's statistical test (Ducoulombier et al., 2004; Zehender et al.,
2005). The Mantel's test, based on comparison of matrixes of genetic
and phenotypic distances, determines whether the sequences in one
compartment are more similar to each other than to the sequences in
other compartments. A total of 70 inter-compartment comparisons
were made using the sequences from the various compartments
(Table 2). The Mantel's test revealed 14 out of 15 subjects with
signiﬁcant genetic differences between serum and at least one of the
tissue compartments at the pre-transplant time point. It is noticeable
that genetic differences between serum and liver were detected in 9
out of 10 subjects with mild recurrent disease compared to 2 out of 5
with severe recurrent disease, suggesting a correlation between
serum versus liver genetic differences and a higher probability of
developing severe recurrent hepatitis C disease after transplant
(p=0.039).
Discussion
Recurrent HCV infection remains to be a universal problem in
patients who are actively infected with HCV and undergo liver
transplantation. Besides, the natural history of HCV disease is
accelerated in the immunosuppressed liver-transplant recipients
compared to immunocompetent patients in the acute infection
setting. In general, the circulating viral titer is one log higher after
transplant than before transplant (Gretch et al., 1995), and severe
graft damage may occur in the early years after transplant (Berenguer
et al., 2000; Gane et al., 1996). The accelerated disease progression in
liver-transplant recipients allows precise deﬁnition of disease out-
comes within a relatively short period of follow-up. Thus, the liver
transplantation model provides a unique opportunity to understand
the pathogenesis of HCV-related liver disease.
Our study investigated the correlation between pre-transplant
HCV genetics and the clinical and histological recurrent hepatitis in
liver-transplant recipients.We analyzed HVR1 of the E2 gene since themultiple compartments studied. The tree was constructed with the neighbor-joining
s of genotypes 1a or 1b (1a.US.JL_77, 1a.US.PEN_77, 1a.H77, 1b.KR.HCV-L2, 1b.JP.11-4)
outgroup. The variants were labeled with patient numbers (M1–M3, M5–M11, S1–S5),
le bar indicates the horizontal branch length corresponding to 5 substitutions per 100
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Fig. 3. Comparison of the genetic parameters of multiple compartments between patients with mild and severe recurrent disease. (A) The mean values of synonymous nucleotide
substitutions (dS); (B) themean values of non-synonymous nucleotide substitutions (dN); (C) themean values of dN/dS ratios; (D) themean values of nucleotide genetic distances;
(E) the mean values of amino acid genetic distances. The Mann–Whitney U-test was used to compare differences between the groups with mild and severe recurrent disease.
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main target of antibody-mediated neutralization. In the present study,
we observed that the genetic diversity of HCV variants is signiﬁcantly
associated with the recurrence of mild hepatitis. Heteroduplex
mobility analysis of pre- and post-transplant serum specimens
demonstrated a clear, direct correlation between HVR1 homogeneity
and the onset of severe recurrent hepatitis C disease by 12 months
after transplant. Investigation of different reservoirs further demon-
strated that pre-transplant genetic distances were universally higher
in the patients who subsequently developed mild recurrent disease
compared to those with severe disease. Higher dN/dS ratios, averaged
over the entire HVR1, were found in the patients with mild recurrent
disease, which may reﬂect a protective aspect of stronger host
immune pressure before transplant in the mild disease cases. HCV
genetic differences between serum and tissues were commonly
observed in the allograft recipients before transplant, and genetic
differences between serum and liver were associated with higher
likelihood of mild disease recurrence at statistical signiﬁcance.
Although the pathogenesis mechanism of recurrent hepatitis C is
still not clear, the correlation between increased HCV genetic diversity
and mild post-transplant hepatitis has been reported in numerous
studies. The degree of relatedness between pre- and post-transplantHCV genetics tended to be higher in patients with severe compared to
those with mild disease recurrence (Gretch et al., 1996; Sanchez-
Fueyo et al., 2001). In other studies, direct sequencing indicated that
intra-sample genetic distances and amino acid diversiﬁcation were
inversely related to the histological severity of HCV recurrence (Lyra
et al., 2002; Sanchez-Fueyo et al., 2001). Furthermore, the greater
genetic divergence was observed in multiple regions over the whole
HCV genome in patients with mild post-transplant disease than in
those with severe disease (Gretch et al., 1996; Sullivan et al., 1998).
The dN/dS ratio, which generally decreased in the broadly immuno-
suppressed patients after transplant, was reported to be lower in
patients with severe than in those with mild or moderate HCV
infection recurrence (Gretch et al., 1996; Sanchez-Fueyo et al., 2001).
Thus, a stronger selective pressure is associated with a better outcome
in the post-transplant setting.
When assessed with statistical methods, genetic differences were
found among HCV variants from the pre-transplant serum, liver,
lymph node, and PBMC specimens in the allograft recipients. HCV
variants circulating in serum are considered as the main source of
allograft reinfection after transplant, whereas lymphocytes and
macrophages also enter the allograft soon after transplant. In theory,
extrahepatic strains in the serum or lymphocytes may compete with
Fig. 4. Genetic diversity of HCV variants among multiple compartments shown with heteroduplex mobility analysis. The HMA gel shift presented the migration distances of
heteroduplex bands along with the homoduplex control after electropheresis. The lanes on the gel shift were labeled with H for homoduplex, S for serum, L for liver, N for lymph
node, and P for PBMCs. The composition of the major variants in each compartment (equal or more than two clones in a single compartment) was shown in the bar ﬁgure with
unique variants labeled with letters. The alignment of the nucleotide sequences was shown right below. (A) Variants from a representative patient with mild post-transplant
outcome (M5); (B) variants from a representative patient with severe post-transplant outcome (S5).
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selective population to dominate within the allograft during the ﬁrst
few hours after reperfusion (Hughes et al., 2004). In the current study,
we found that the patients with heterogeneous HCV variants,
especially those with genetic differences between liver and serum,
were more likely to develop mild post-transplant disease. This
observation suggests that liver-derived and extrahepatic variants
may both contribute to reinfection of the naive allograft and inﬂuence
the development of recurrent hepatitis. In contrast, when pre-Table 2
Results of the Mantel's test performed between the pairwise compartments in the
patients with mild and severe recurrent hepatitis. P value of less than 0.05 in the
Mantel's test is considered as an indication of signiﬁcant genetic differences.
Mild Severe P value
Signiﬁcant Non-signiﬁcant Signiﬁcant Non-signiﬁcant
Serum vs.
Liver 9 1 2 3 0.039
LN 4 3 1 2 0.490
PBMC 6 2 2 3 0.207
Liver vs.
LN 3 4 2 1 0.490
PBMC 6 2 2 3 0.207
LN vs.
PBMC 4 2 1 2 0.343
Note. The Pearson Chi-square test was used to compare the frequency of genetic
differences between the two groups with mild and severe recurrent disease.transplant genetic differences are not observed, allograft reinfection
may be dominated by liver-derived variants that are the major
variants in circulation as well as in extrahepatic compartments.
The association between HCV genetic diversity and progression of
post-transplant disease suggests two possible explanations. First, the
histological switch to severe recurrent disease might simply be a
consequence of re-infection with highly pathogenic variants that
dominate at the pre-transplant stage. The pathogenic variants rapidly
adapt to the naive allograft to propagate a large amount of homoge-
neous descendants followedwith the recurrence of severe liver disease.
The analogous model of acute infection seems to support the enhanced
inherent virulence of speciﬁc variants, when extreme high levels of HCV
titer were observed with the lowest degree of genetic diversity in
patients with fulminant hepatitis (Farci et al., 2000). In the transplan-
tation setting, it is noteworthy that multiple factors such as age of
recipients, severity of hyperbilirubinemia, variable immunosuppression
level, and HLA mismatch between donors and recipients may also
contribute to the outcome of recurrent disease along with the factor of
HCV genetics, whichmakes the situation even complicated. Second, the
HCV genetic diversity at both pre- and post-transplant stagesmight be a
consequence of host antiviral immune defense, which drives viral
mutation and protects the liver from the development of severe disease.
In such case, the HCV genetic diversity is rather a co-occurrence during
the development of post-transplant liver disease. Our current data
presented higher dN/dS ratio in the patients with mild recurrent
disease, suggesting that host immune pressure is more prevalent at the
pre-transplant stage in the mild cases. Immunology data in a study by
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correlation between markers of HCV-speciﬁc CD4+ T cell immunity
during the early post-transplant infection period and mild disease
phenotypes.
When assessing viral heterogeneity from tissue compartments and
serum, a major concern is sampling bias. This can occur if the viral
genome variants are non-uniformly distributed throughout the
infected tissue. A second type of sampling bias, referred to as
“resampling bias” (Liu et al., 1996), occurs when genome template
input copy number is very low. Regarding the ﬁrst issue, extensive
tissue samplingwas performed on twowhole explanted HCV-infected
livers at 10 independent and spatially separated sites per liver (data
not shown). HCV genetic heterogeneity was very close or identical for
all samples, suggesting that HCV genome distribution is most likely
uniform in liver at end-stage disease. Regarding the issue of
“resampling bias”, which has been documented in the setting of low
titer HIV infections (Liu et al., 1996), we found no evidence of
resampling in the few cases where repeat testing was performed,
although the possibility of this ampliﬁcation error may not be with
conﬁdence excluded during our study of HCV heterogeneity in tissue
reservoirs (data not shown).
In summary, our data suggest that HCV genetics at the pre-
transplant stage predicts hepatitis C disease severity in transplanted
allograft. Viral predictors of poor outcome include low genetic
diversity in circulation and decreased genetic differences between
serum and tissue specimens. Longitudinal studies are still going on in
our laboratory to further deﬁne the HCV pathogenic mechanism that
determines the outcome of hepatitis C disease after transplant.
Methods
Patients and sample collection
The study group comprised 56 patients who underwent orthotopic
liver transplantation at the University ofWashingtonMedical Center, as
described previously (Pal et al., 2006). Informed consent to participate
in the study was obtained from all patients in accordance with the
institutional review board requirements. All patients had HCV-related
end-stage liver disease at the time of liver transplantation, and all
developed recurrent HCV infection as demonstrated by the persistence
of post-transplant HCV viremia. HCV genotypeswere assigned using the
restriction fragment length polymorphismanalysis (RFLP) of the 5′-UTR
(Davidson et al., 1995) and conﬁrmed by probe hybridization of the
Core/E1 region (Li et al., 2008b). Serumsamples and puriﬁed peripheral
blood mononuclear cells (PBMCs) were obtained immediately prior to
liver transplantation and stored at −80 °C. For 15 patients, liver and
perihepatic lymph node specimens were collected at the time of liver
transplantation, immediately snap frozen in optimal cutting tempera-
ture (OCT) compound (Sakura Finetek, Torrance, CA), and stored at
−80 °C until further analysis. Serum samples were further obtained
from 51 patients at around 12 months after transplant to deﬁne the
genetic kinetics of recurrent HCV variants. Protocol liver biopsies were
performed serially after transplant to monitor the recurrence of
hepatitis C disease in the allograft. A median of 6 liver biopsies per
patient was performed in a follow-up period of a median of 33 months,
and disease severity was evaluated by an experienced transplant
pathologist according to the Batts–Ludwig system (Batts and Ludwig,
1995).
RNA extraction, RT-PCR, and sequencing
RNA was extracted from sera with the QIAamp Viral RNA mini kit
(QIAGEN Inc., Valencia, CA) or from tissues with the RNeasy Mini kit
(QIAGEN) according to the manufacture's instructions. cDNA synthesis
was carried out with the Moloney Murine Leukemia virus reverse
transcriptase (Invitrogen, Carlsbad, CA) as described previously (Li et al.,2008a). Ampliﬁcation of a 165-nucleotide sequence encompassing the
HVR1 region was performed by nested PCR using two pairs of primers
originally described by Weiner et al. (1991). Heteroduplex mobility
analysis was applied to compare the difference of genetic diversity of
HCV variants among the specimens from the same individuals
(described below). For the 15 patients with multiple compartments
available, the ampliﬁed fragmentswere further puriﬁed and ligated into
the TA cloning vector (Invitrogen, Carlsbad, CA) and transfected into
Escherichia coli TOP-10 competent cells. Eighteen to twenty-three
colonies per specimen were then selected for clonal frequency analysis
of unique variants (Wilson et al., 1995), and clones representing unique
migration patterns during the gel electrophoresis were picked up for
nucleotide sequencing in both directions.
Heteroduplex mobility analysis of HVR1 variants
HVR1 variants of pre- and post-transplant serum samples or tissue
specimens were evaluated by heteroduplex mobility analysis (HMA)
using speciﬁc probes generated from the major variant of the pre-
transplant serum of each subject (Gretch et al., 1996; Polyak et al.,
1997; Wilson et al., 1995). Probe labeling and hybridization were
performed as described previously (Sullivan et al., 1998). Puriﬁed
probes were end-labeled with T4 polynucleotide kinase plus 32P ATP
(Amershan, Arlington Heights, IL) and then hybridized to HVR1
fragments derived by PCR ampliﬁcation from each specimen.
Hybridization mixtures were separated by electrophoresis on 6%
polyacrylamide MDE gel (Cambrex, Rockland, ME) that was later
vacuum dried and exposed to X-ray ﬁlm. Hybridization to the
unlabeled probe itself served as a marker for identiﬁcation of
homoduplexes. Heteroduplex mobility ratio (HMR) was estimated
as the ratio of the shift distance of heteroduplex bands from the top of
the gel compared to that of homoduplexes.
Phylogenetic and statistical analyses
HVR sequences were aligned using the CLUSTAL W program
(Thompson et al., 1994) included in the MacVector 9.0 (Symantec
Corp., Cupentino, CA). Genetic distances were calculated by the
PHYLIP version 3.66 using Kimura's two-parameter model and an
empirical transition/transversion ratio of 2 (Felsenstein, 1993).
Synonymous (dS) and non-synonymous (dN) substitutions were
estimated for the HVR1 sequences by the Nei and Gojobori method
(Nei and Gojobori, 1986). Phylogenetic trees were constructed with
the neighbor-joining algorithm based on the nucleotide sequences of
HVR1 variants (Saitou and Nei, 1987).
In the study including the 56 subjects, the Pearson Chi-square test
was used to evaluate the gender and genotype according to groups of
disease recurrence, while the Mann–Whitney U-test was used to
compare the other clinical characteristics and genetic diversity
between the groups with the mild and severe disease outcomes.
The Mann–Whitney U-test was also used in the tissue reservoir
studies of the 15 subjects to analyze the difference of the nucleotide
substitutions and genetic distances between the groups withmild and
severe recurrence. The Mantel's test was used to determine the
genetic differences of the HCV variants, in other words, if the variants
detected from a given compartment were genetically closer to each
other than to variants detected from a different compartment
(Ducoulombier et al., 2004; Zehender et al., 2005). The Pearson Chi-
square test was used to compare the frequencies of genetic differences
between the groups with mild and severe recurrence.
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